Pharm exam 1: section 3 Flashcards

(45 cards)

1
Q

Anticoagulation

Indications

A
Venous thromboembolism: prevention and tx
Stroke prevention in setting of afib
Ischemic stroke
Prosthetic cardiac valve
Coronary and PVD
Hypercoagulable disease

Prophylaxis for clotting events in high risk pt that might have high risk procedure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Warfarin

A

Vitamin K antagonist

Inhibits synthesis of Vitamin K dependent clotting factors:
X
IX
VII (half life = 6 hrs)
II (prothrombin) (half like 60 hours)
Coagulation inhibitor proteins C, Z, S
Average half life 36-42 hrs (3-4 days)
Onset: depends on time needed to deplete factors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Warfarin

Pharmacokinetics

A

Well absorbed PO

Metabolized by enzymes CYP1A2 & CYP2CP

Precautions and C/I

  • Pregnancy category X
  • Cautious use in pt w/ fall risk, dementia, or uncontrolled HTN
  • avoid: recent hemorrhagic stroke, active bleeding, recent trauma/surgery, presence of spinal catheter, aneurysm, CNS tumor
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Warfarin

Adverse reactions

A

Bleeding
-antidote is vitamin K

Allergic reactions

Drug interactions

  • simvastatin, fish oil, garlic, prednisone may increase INR
  • Phenytoin and phenobarbital may decrease INR
  • decreased by foods w/ vitamin K
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Warfarin

* never initiated at mono therapy bc takes a long time for warfarin to reach full therapeutic effect

A
Clinical Dosing
Start @ 5mg/day (7.5mg/day if weight > 80 kg)
Consider lower dose if:
> 75 yo
Multiple cormorbidities
Elevated liver enzymes
Changing thyroid status

INR hows prolongation w/in 3 days after starting d/t rapid depletion of factor VII
Full anticoagulation after depletion of factor II depleted (2-14 days)

Check daily until in range on 2 consecutive days
Check 2x weekly for 1-2 weeks
Then less frequently (@ least every 6 weeks)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Warfarin

Target INR

A
INR 2-3 
VTE
DVT
stroke prevention in afib
valves
hypercoagulable condition

INR 2.5- 3.5
Heart valvle
hypercoagulable condition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Direct acting Oral anticoagulants

Dabigatran (Pradaxa)

A

Direct thrombin inhibitor
Poor bioavailability
formulated as prodrug

Few drug interactions
Renal clearance
Half life: 14-17hrs

Avoid in pt w/:
CrCl <15 ml/min
dialysis
prosthetic heart valve

Adverse reactions
bleeding (administer fresh frozen plasma)
GI vs intracranial bleeding
GI effects

Drug -drug interactions

  • quinidine: increase levels by 100%
  • amiodarone: increase levels by 50%
  • rifampin: may decrease effects
  • PPIs and antacids - separate doses by 2 hrs

Dosing: reduce risk of CVA in pt w/ afib
150mg BID - normal renal function
75mg BID - decreased renal function

Check hepatic function at baseline and periodically if concern
Cannot crush
Cannot be put in pill box bc its packaged in moisture proof container

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Direct acting oral anticoagulants
Rivaroxaban (Xarelto)
PE tx
DVT prevention

A

Direct thrombin inhibitor
Poor bioavailability
formulated as prodrug

Few drug interactions
Renal clearance
Half life: 14-17hrs

Avoid in pts w/ heart valve
Avoid in CrCl < 30ml/min
must be taken with food to improve bioavailability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Direct acting oral anticoagulants

Apixaban (Eliquis)

A

Direct thrombin inhibitor
Poor bioavailability
formulated as prodrug

Few drug interactions
Renal clearance
Half life: 14-17hrs

Least dependence on CrCl
good for pts w/ kidney function issues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Direct acting oral anticoagulants

Edoxaban( Savaysa)

A

Less drug-drug interactions

Cannot use in CrCl: >95ml/min -> cause stroke

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Direct acting Oral anticoagulants

Indications

A

DVT and PE treatment
DVT prevention
stroke

Bind to factor Xa: Block thrombin

faster onset than warfarin; injectable bridge therapy not necessary as with warfarin
no dietary interactions
dosing adjustment not necessary

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Direct acting oral anticoagulants

Transitioning

A

From warfarin:
start when INR at lower end of therapeutic range

From unfractionated heparin:
start when heparin is discontinued

From low molecular weight heparin (LMWH):
start when LMWH due next (usually 12 hrs from last dose)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Heparin

A

Binds w/ antithrombin III
inactivates factors IXa, Xa,XIIa, XIII

Given: IV or subQ (immediate action - emergency situations)
Not absorbed in GI

Extensively protein bound
Metabolized by liver / renal excretion

Caution in Pregnancy; category C
Avoid in advanced hepatic or renal disease
Avoid in bleeding disorder or active bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Heparin

Adverse reactions

A

HIT (immune response to heparin)
Life threatening bleeding
Pain at injection site, bruising: subQ

Antidote: protamine sulfate

Drug interactions
Cephalosporins and PCNs
warfarin, antiplatelets, thrombolytics
Valproic acid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Heparin
Dosing
Indications

A

Given 12 hrs pre-op
Maintenance q 8-12 hrs for 7 days post op

Monitor:
aptt
platelet and hematocrit q 2-3 days initially

Indications
acute thromboembolism
VTE prophylaxis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

LMWH

A

Fragments of unfrationated heparin

Inactivates thrombin and factor Xa

No lab monitoring
Fixed dosing at prophylaxis: aptt may not be significantly prolonged at prophylaxis doses

Weight based with therapeutic dosing: At therapeutic doses aptt prolongation not used to measure therapeutic effect

Half life: 108-252 minute

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

LMWH

Enoxaparin

A

DVT or PE

Pre-op given 12 hrs before surgey

Still at risk for HIIT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

LMWH

Fondaparinux

A

DVT

Hip fracture surgery or knee replacement

Risk for HIIT is subsequently lower

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Education considerations

Warfarin

A

Dosing may vary from day to

Pills are different size and color for dose

Must explicitly state each day pt takes a certain dose to avoid miscommunication

Educate about INR checks

Warn of bleeding complication

Educate about food (leafy greens, asparagus, onion, garlic)

20
Q

Education consideration

LMWH

A

Subq administered at home

Show how to administer

Rotate sites

Bleeding

21
Q

Antiplatelet drugs
Aspirin
Must inform provider taking med

A
Inhibits cyclooxyrgenase (COX)
Interferes w/ platelet aggregation

Well absorbed PO; take with food to be prevent GI distress)

Metabolized in liver

Renally excreted (pH affects excretion)

Contraindications
Hypersensitivity
cross sensitivity w/ NSAIDS
Pregnancy category C (D in 3rd trimester)
Reye's syndrome in children

Adverse reactions
bleeding
GI upset and bleeding
salicylism (tinnitus)

Interactions
other anti platelet, anticoagulant, fibrinolytic
Herbals (ginko, garlic, ginseng)
NSAIDS

Dosing
MI prevention: 75-162mg daily
afib: 75-325mg
CVA or TIA: 50-100mg daily

Education
take with a full glass of water
ASA must be stopped 7 days before surgery

Adverse:
ASA toxicity: tinnitus, dizziness
cerebral edema
seizure
bleeding or bruising
22
Q

Antiplatelet drug

Aggrenox

A

Combination product (25mg ASA/ 200mg ER dipyridamole)

Dipyridamole inhibits platelet adhesion but MOA unknown

23
Q

Antiplatelet drugs

Ticlodipine and clopidogrel

A

Reduce platelet aggregation by inhibiting adenosine diphosphate (promoter of platelet receptor binding)

Contranindication
avoid in pt w/ liver dysfunction

rapidly absorbed after PO admin
metabolized in liver
half life lengthens w/ repeated dosing
decreased renal clearance w/ age

Adverse reactions
neutropenia

Interactions
antacids
digoxin
cimetidine

Dosing
Stroke prevention in ASA intolerant pts: 250mg BID

24
Q

clopidogrel

A

Reduce platelet aggregation by inhibiting adenosine diphosphate (promoter of platelet receptor binding)

Contranindication
avoid in pt w/ liver dysfunction

prodrug
excreted in urine and feces

Adverse reaction
bleeding

Interactions
proton pump inhibitors
CYP2C 19 inhibotors

Dosing
MI prevention: 75 mg daily
ST elevation ACS: 300mg daily < 75ys
                               75mg daily > 75yrs
Secondary CVA prevention 75mg

Education
Separate doses of clopidogrel and PPIs

25
Hematopoetic Growth Factors | Treat anemia
Epoetin alfa (Epogen, EPO, Procrit) and darbepoetin alfa (Aranesp) -Stimulate erythropoiesis -Used for treatment of anemia due to end stage renal disease, AIDS or chemotherapy -Preoperatively to prepare for allogeneic transfusions ``` Granulocyte colony stimulating factor filgrastim [Neuopgen] pegfilgrastim [Neulasta] tbo-filgrastim [Granix]) Stimulates granulocyte formation ``` Use Neutropenia due to bone cancer and chemotherapy
26
Hematopoetic Growth Factors
Pharmacokinetics Well absorbed SubQ Metabolism and excretion not well understood ``` Precautions and contraindications Epoetin alfa & darbepoetin alfa HTN is only contraindication Increased risk of tumor growth Pregnancy Category C ``` Filgrastim & pegfilgrastim Hypersensitivity to E. coli Pregnancy Category C
27
Hematopoetic Growth Factors
Adverse Drug Reactions All can produce bone pain (large bones - Sternum -> feels like MI pain; femur and pelvis) Epoetin alfa & darbepoetin Seizures / HTN (don't give to HTN pts) Decreased overall survival rate and/or tumor growth in patients with certain cancers Filgrastim & pegfilgrastim Hypersensitivity Drug Interactions
28
Hematopoetic Growth Factors
Goal: prevent transfusion Renal pts that are transplant candidates Antibody exposure -> effects tissue typing that occurs Hgn 11-12 range Clinical Use and Dosing Epoetin alfa to treat anemia, CKD, chemo, HIV 50-150 mcg/kg 3 times a week Dose dependent on diagnosis For allogeneic transfusion: 300 mcg/kg/d given 10 days prior to surgery, day of surgery and for 4 days after surgery Darbepoetin: CKD and chemo 0.45-2.25 mcg/kg once weekly
29
Hematopoetic Growth Factors
Monitoring Darbepoetin alfa: Hgb weekly, ferritin periodically Epoetin alfa: Hct weekly, ferritin periodically, monitor BP cannot receive if BP is high Patient education Administration Self administration of SubQ medication Use of iron supplements Adverse drug reactions HTN and allergic reactions
30
Anemia Pathophysiology
Iron deficiency anemia Decreased iron carrying capacity of the blood Inadequate intake or blood loss (acute or chronic) Gastric bypass pt: cannot absorb enough iron Treated with iron replacement Folic Acid Deficiency Anemia Seen in alcoholics, chronic malnutrition, fad diets, and diets low in vegetables Drugs: Dilantin, sulfamethoxazole/trimethoprim, and oral contraceptives, methotrexate Pernicious anemia Vitamin B12 deficiency leads to macrocytic-normochromic anemia (large cells, normal in color) Vegetarians, vegans, genetic predisposition, autoimmune disease
31
Iron deficiency Anemia
Prevention Adequate intake via iron-rich diet (difficult w/ gastric bypass pts) Monitor in periods of rapid growth (infancy, adolescence, pregnancy): increased risk bc needs are higher Replacement in infants 1 mg/kg/day starting at 4 months (2 mg/kg/d in preterm infants) Treatment Oral vs. intravenous Oral - once daily dosing or even once every other day dosing Better GI tolerance every other day and equally efficacious
32
Iron deficiency Anemia
Monitoring - Reticulocyte count 5-10 days after starting therapy - Hgb, Hct, ferritin at 4 weeks and then at 3 months and annually Outcome evaluation Return to normal Hgb, Hct and ferritin levels If Hgb, Hct and ferritin do not return to normal levels the patient should be evaluated for a source of blood loss or other pathology * CANNOT be iron deficient if ferritin is normal and iron is low
33
Iron deficiency Anemia
Patient Education Importance of prevention with adequate iron intake in diet Administration Empty stomach if tolerated with ½ glass of orange juice Daily or every other day is best Constipation (may need a stool softener) Avoid calcium-rich foods/supplements when taking iron
34
Iron preparations
Iron preparations build serum iron and iron storage in the body Enhanced absorption if iron stores low Ferrous form is absorbed more readily Food affects absorption - take on empty stomach Eliminated via shedding of GI mucosal cells or via bleeding
35
Iron Contraindications | Adverse reactions
Precautions and Contraindications Hemochromatosis and hemolytic anemia Adverse Drug Reactions GI symptoms (constipation, GI upset) Acute toxicity possible especially in children Drug interactions Chelation (abx) Decreased absorption decreased w/ aluminum, magnesium, calcium Acid: ascorbic acid enhances absorption
36
Iron Dosing
``` Clinical use and dosing Iron deficiency anemia Adults 150-300 mg elemental iron daily Treat for 3 to 4 months after Hgb/Hct return to normal Premature infants 2-4 mg/kg/day Infants and young children 4-6 mg/kg/day ``` Monitoring Reticulocyte count 7-10 days after starting therapy Hgb at 2 weeks, then based on individual risk
37
Iron | Pt education
Patient Education Prevention Adequate intake of iron in diet Administration Take on empty stomach if tolerated (w/ orange juice) Take with Vitamin C to enhance absorption Avoid taking with dairy products, calcium, antacids Adverse Reaction Constipation (stool softener, laxative) Acute iron toxicity if overdose, keep away from children
38
Folic acid deficiency anemia
Risk groups Infants fed goat’s milk or powdered milk formula Vegetarians and vegans Pregnancy increases daily requirement need Patients with Celiac disease, Crohn’s disease giardial infections short bowel syndrome Drugs that affect folic acid absorption Prevention Adequate dietary intake Folic acid supplementation in pregnancy
39
Folic acid deficiency anemia
Drug therapy for deficiency Oral folic acid 1mg/day for 4 to 5 weeks Hgb levels start to rise in a week Women of childbearing age and pregnant women should consume 0.4-0.8 mg/day even if not deficient Monitoring Follow Hgb/Hct in 4 weeks and then regularly Education Length of need for folic acid Indefinite folic acid tx for malnutrition ``` Side effects: skin rash irritability impaired judgement altered sleep pattern abd distention nausea ``` Serum folic level - 1mg
40
Pernicious Anemia
Pernicious anemia is caused by deficiency in Vitamin B12 Defective secretion of gastric intrinsic factor, which is necessary for vitamin B12 absorption Vitamin B12 malabsorption occurs in 10-30% of adults > age 50 due to reduced pepsin activity and gastric acid secretion Prevention Eat foods high vitamin B12, such as mollusks (e.g., clams), fortified breakfast cereals, liver, trout, salmon, milk, and eggs Diet cannot fix pernicious anemia
41
Pernicious anemia | Drug therapy
Oral, IM, SC and intranasal Vitamin B12 replacement Nutritional deficit: 1000 mcg/day of cyanocobalamin is given until B12 normalizes Pernicious anemia: Vitamin B12 therapy 1,000 mcg IM daily for 1 week followed by 100 to 1,000 mcg IM weekly for a month Parenteral, nasal, or oral therapy may be used once a patient’s B12 levels return to normal. Parenteral: 1,000 mcg cyanocobalamin IM monthly Nasal: 500 mcg of cyanocobalamin weekly Oral: 1,000 mcg daily (least expensive), easiest
42
Pernicious anemia
``` Monitoring: Reticulocyte counts Hgb and Hct iron folic acid vitamin B12 serum levels prior to treatment, at 5 to 7 days of therapy, then frequently until the Hgb and Hct are normal ``` Monitor potassium levels Liver function tests every 2 to 4 weeks to monitor for hepatotoxicity
43
Pernicious anemia
Patient Education Disease process and need for life long therapy Vitamin B12 therapy regimen Monitoring
44
Anemia of chronic disease
Occurs due to a inflammatory disease process Older adults predisposed ``` Patients with osteomyelitis tuberculosis rheumatoid diseases hepatitis, carcinoma myeloma lymphoma leukemia at risk ``` Much less likely to respond to epoetin Treat underlying disease Patients with chronic kidney disease will respond to erythropoietin agents
45
Anemia of chronic disease
Treatment If associated with chronic renal failure or zidovudine-treated HIV : epoetin alfa 50-100 units/kg in adults 50 units/kg in children dosed three times a week Epoetin alpha dose is titrated to keep Hgb level between 9 – 10.5g/dL Dosage is increased by 25 percent if Hgb <9 g/dL Epoetin alpha dose is decreased by 25 percent if hemoglobin approaches 12 g/dL or Hgb increases more than 1 g/dL in any 2-week period